Table 3 Crude disease rates and hazard ratios of incident CVD outcomes

From: Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study

  Total, PY: 31 255 ADT used, PY: 7527 ADT not used, PY: 23 728 All patients ( n =7637) Patients without preexisting CVD ( n =5972) Patients with preexisting CVD ( n =1665)
CVD N Crude rate a N Crude rate N Crude rate Adjusted HR 95% CI Adjusted HR 95% CI Adjusted HR 95% CI
Cardiac ischaemia
AMI 431 13.79 139 18.47 292 12.31 1.19 0.95, 1.49 1.24 0.93, 1.64 1.14 0.78, 1.65
Angina 61 1.95 18 2.39 43 1.81 0.95 0.52, 1.75 0.64 0.24, 1.67 1.31 0.58, 2.93
Cardiac arrest 58 1.86 19 2.52 39 1.64 1.15 0.62, 2.12 1.29 0.61, 2.76 0.85 0.25, 2.83
Total 550 17.68 176 23.38 374 15.76 1.15 0.95, 1.41 1.18 0.91, 1.52 1.13 0.82, 1.57
Stroke
Total 71 2.27 23 3.06 48 2.02 1.09 0.63, 1.88 0.93 0.46, 1.88 1.62 0.64, 4.12
Other heart diseases
Arrhythmia 564 18.05 176 23.38 388 16.35 1.17 0.96, 1.43 1.07 0.84, 1.37 1.44 1.02, 2.01
Heart failure 689 22.04 244 32.42 445 18.75 1.27 1.06, 1.51 1.81 1.40, 2.32 1.00 0.78, 1.29
Cardmyopathy 36 1.15 16 2.13 20 0.84 1.84 0.87, 3.88 2.25 0.74, 6.78 1.51 0.51, 4.46
Conduction disorder 81 2.59 27 3.59 54 2.28 1.40 0.84, 2.35 1.08 0.57, 2.03 3.11 1.22, 7.91
Hypertensive heart disease 3 0.1 1 0.13 2 0.08 NA NA NA NA NA NA
Valvuopathy 67 2.14 22 2.92 45 1.90 1.22 0.69, 2.17 1.08 0.53, 2.21 1.59 0.59, 4.26
Total 1440 45.64 486 64.56 954 40.21 1.25 1.11, 1.42 1.34 1.14, 1.58 1.22 1.01, 1.47
  1. Abbreviations: ADT=androgen deprivation therapy; AMI=acute myocardial infarction; CI=confidence interval; CVD=cardiovascular disease; HR=hazard ratio; NA=not applicable; PY=person-years.
  2. HRs adjusted for: ADT (time dependent), hypertension (Y/N), diabetes (Y/N), Gleason scores (<7/7/>7), stage at diagnosis (T1/T2/T3), grading for PC (1/2/3/4), year of PC diagnosis (<2000/2001–2005/2006), race (White/African/Asian/Hispanic), age (>65/ 65 years), calcium channel blockers (time dependent), anticoagulants (time dependent), antilipemics (time dependent), digoxin (time dependent), nitrates (time dependent), antidiabetic drugs (time dependent), baseline PSA level ( 4/4–10/10–20/>20), risk group (low/intermediate/high), and Charlson score 1 year before diagnose (0/1–2/3). Bold values: 95% confidence intervals do not include 1.00.
  3. aCrude rate: rate per 1000 person-years.